Literature DB >> 3242580

Haem arginate improves hepatic oxidative metabolism in variegate porphyria.

O Tokola1, P Mustajoki, J J Himberg.   

Abstract

1. The elimination of antipyrine was investigated before and after intravenous administration of haem arginate (3 mg haem kg-1 day-1 on three or four successive days) to six patients with variegate porphyria in remission. 2. Haem arginate decreased the faecal content of protoporphyrin from 557 +/- 91 to 118 +/- 32 (mean +/- s.e. mean) and of coproporphyrin from 144 +/- 19 to 19 +/- 3 nmol g-1 dry weight. 3. Before haem treatment antipyrine elimination half-life was long (30.5 +/- 5.6 h), but the treatment decreased it to 6.3 +/- 0.8 h. Antipyrine clearance increased from 0.25 +/- 0.05 to 1.03 +/- 0.11 ml min-1 kg-1 (P less than 0.001), being 4.6 times higher after haem arginate infusions. 4. The volume of distribution of antipyrine did not change. 5. The severe impairment of hepatic mixed function oxidase activity even in the symptomless stage of porphyria indicates cautious dosage of drugs primarily eliminated by hepatic oxidative reactions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3242580      PMCID: PMC1386591          DOI: 10.1111/j.1365-2125.1988.tb05315.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  An investigation of porphyria cutanea tarda.

Authors:  G HOLTI; C RIMINGTON; B C TATE; G THOMAS
Journal:  Q J Med       Date:  1958-01

2.  Haem arginate in the treatment of acute hepatic porphyrias.

Authors:  P Mustajoki; R Tenhunen; O Tokola; G Gothoni
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-30

3.  Haem arginate in acute hepatic porphyrias.

Authors:  V Kordac; P Martásek
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

4.  Pharmacokinetics of intravenously administered haem arginate.

Authors:  O Tokola; R Tenhunen; L Volin; P Mustajoki
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

5.  Instability of hematin used in the treatment of acute hepatic porphyria.

Authors:  C A Goetsch; D M Bissell
Journal:  N Engl J Med       Date:  1986-07-24       Impact factor: 91.245

Review 6.  Suicidal destruction of cytochrome P-450 during oxidative drug metabolism.

Authors:  P R Oritz de Montellano; M A Correia
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

7.  Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria.

Authors:  K E Anderson; A P Alvares; S Sassa; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

8.  Effect of heme on allylisopropylacetamide-induced changes in heme and drug metabolism in the rhesus monkey (Macaca mulatta).

Authors:  U Muller-Eberhard; J L Eiseman; M Foidart; A P Alvares
Journal:  Biochem Pharmacol       Date:  1983-12-15       Impact factor: 5.858

9.  Structural and functional reconstitution of hepatic cytochrome P-450 in vivo. Reversal of allylisopropylacetamide-mediated destruction of the hemoprotein by exogenous heme.

Authors:  G C Farrell; M A Correia
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

10.  The inherited enzymatic defect in porphyria variegata.

Authors:  J C Deybach; H de Verneuil; Y Nordmann
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

View more
  1 in total

Review 1.  Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Authors:  Petro E Petrides
Journal:  Diagnostics (Basel)       Date:  2022-07-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.